1. Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac: interim guidance, first issued 24 May 2021, updated 21 October 2021, updated 15 March 2022;World Health Organization,2022
2. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry;Strangfeld;Ann Rheum Dis,2021
3. Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial;Medeiros-Ribeiro;Nat Med,2021
4. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study;Furer;Ann Rheum Dis,2021
5. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort;Geisen;Ann Rheum Dis,2021